...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Number of shares to compute the price per share

Some on this hub feel there maybe a buyout of Zenith Epigenetics ??  some have said it is much easier to buyout a private biotech than a public company.  That maybe true but we have seen zero trial results from the Zen 3694,  I wonder if this is by design by management.....? here is hoping for a buyout or deal, sure would help with a proper valuation for RVX....

Share
New Message
Please login to post a reply